Nextcure ( (NXTC) ) has released its Q1 earnings. Here is a breakdown of the information Nextcure presented to its investors.
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer patients who do not respond to existing treatments, using targeted therapies like antibody-drug conjugates.
In its latest earnings report for the first quarter of 2025, NextCure highlighted progress in its LNCB74 antibody-drug conjugate program, which is currently in Phase 1 trials for multiple cancers. The company also shared financial results and strategic plans for its preclinical programs.
Key financial metrics showed a decrease in research and development expenses to $7.9 million from $11.4 million in the same quarter of the previous year, attributed to reduced costs in non-LNCB74 programs and restructuring efforts. The net loss for the quarter was $11.0 million, an improvement from the $17.1 million loss in the first quarter of 2024. The company reported cash reserves of $55.9 million, expected to support operations into the second half of 2026.
Strategically, NextCure is expanding its clinical trial sites for LNCB74 and plans to initiate backfill cohorts later in 2025, with a proof of concept data readout anticipated in the first half of 2026. Additionally, the company is seeking partnerships for its preclinical programs targeting Alzheimer’s disease and osteogenesis imperfecta, with potential investigational new drug filings in the next 12 to 18 months.
Looking ahead, NextCure remains focused on advancing its clinical and preclinical programs, leveraging its expertise in biological pathways and biomarkers to develop therapies that address unmet needs in cancer treatment.